Prices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. pharma, explaining how reference-based pricing compresses margins and forces brands to compete on loyalty, adherence, and the quality of their support programs. When physicians and patients see real-time costs at the point of prescribing, “comparable” op...
All content for Postscripts Rx is the property of PostScripts Rx Team and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Prices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. pharma, explaining how reference-based pricing compresses margins and forces brands to compete on loyalty, adherence, and the quality of their support programs. When physicians and patients see real-time costs at the point of prescribing, “comparable” op...
Puppy Parks and AI Agents: September Pharma Events
Postscripts Rx
11 minutes
1 month ago
Puppy Parks and AI Agents: September Pharma Events
Navigating the evolving landscape of pharmaceutical patient support requires staying ahead of emerging technologies and industry trends. In this illuminating conversation with Cathy Zaremba from Medisafe's Marketing team, we dive into key takeaways from two major industry conferences—Hubs West and Fierce Pharma Week—where changing regulations, digital innovation, and artificial intelligence dominated discussions. The pharmaceutical conference landscape itself is transforming. Fierce Pharma W...
Postscripts Rx
Prices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. pharma, explaining how reference-based pricing compresses margins and forces brands to compete on loyalty, adherence, and the quality of their support programs. When physicians and patients see real-time costs at the point of prescribing, “comparable” op...
